Sorivudine
- 1 December 1995
- journal article
- Published by Wolters Kluwer Health in Neurology
- Vol. 45 (12_suppl_8) , S73-S75
- https://doi.org/10.1212/wnl.45.12_suppl_8.s73
Abstract
Sorivudine is a pyrimidine nucleoside analog that has in vitro inhibitory activity against VZV at concentrations of 0.0001 to 0.004 mu g/ml. These concentrations are over 1,000-fold lower than that required for the inhibition of VZV replication by acyclovir. Sorivudine also is an effective inhibitor of herpes simplex virus (HSV)-1 replication with inhibitory concentrations ranging from 0.03 to 0.1 mu g/ml. These concentrations are similar to data for acyclovir. Of note, sorivudine is inactive against HSV-2 and cytomegalovirus. [3]Keywords
This publication has 2 references indexed in Scilit:
- Azole antifungal agents: emphasis on new triazolesAntimicrobial Agents and Chemotherapy, 1988
- Virus drug-resistance: mechanisms and consequencesAntiviral Research, 1984